<DOC>
	<DOCNO>NCT02313298</DOCNO>
	<brief_summary>A single arm phase II study SBRT prostate cancer primarily assess acute late toxicity secondarily PSA outcomes quality life measurement extreme hypofractionated regimen 36.25Gy 5 fraction 10-11 day .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy Organ Confined Prostate Cancer</brief_title>
	<detailed_description>This single arm phase II study SBRT prostate cancer primarily assess acute late toxicity secondarily PSA outcomes quality life measurement extreme hypofractionated regimen 36.25Gy 5 fraction 10-11 day . The radiation therapy deliver use intensity modulate radiotherapy ( IMRT ) aid volumetric image guidance ensure accuracy . Toxicity measure preset interval , HRQOL parameter use Expanded Prostate Index Composite ( EPIC ) questionaire focus bowel , urinary , sexual hormonal symptom .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis adenocarcinoma prostate History/physical examination digital rectal examination prostate within 60 day prior registration Histological evaluation prostate biopsy assignment Gleason score biopsy material ; Gleason score 27 Clinical stage T12b ( DRE ) ( AJCC 7th edition ) within 90 day registration PSA &lt; 20 ng/mL within 60 day prior registration . PSA obtain within 10 day prostate biopsy . ( Every effort make obtain serum PSA value obtain 1 year prior treatment allow calculation PSA kinetics . ) Not one intermediate risk factor ( T2b/GS7/PSA 1020 ) Zubrod Performance Status 01 within 60 day prior registration Age ≥ 21 Patient must able provide studyspecific inform consent prior study entry . Willingness ability complete Expanded Prostate Cancer Index Composite ( EPIC ) questionnaire Prior concurrent invasive malignancy ( except nonmelanomatous skin cancer ) lymphomatous/hematogenous malignancy unless continually disease free minimum 5 year . ( For example , carcinoma oral cavity permissible ; however , patient prior history bladder cancer allow ) Tstage ≥ T2c stag MRI Evidence distant metastasis Regional lymph node involvement Previous radical surgery ( prostatectomy ) , cryosurgery , HIFU prostate cancer Previous pelvic irradiation , prostate brachytherapy , bilateral orchiectomy Previous hormonal therapy , LHRH agonists ( e.g. , goserelin , leuprolide ) LHRH antagonist ( e.g. , degarelix ) , antiandrogens ( e.g. , flutamide , bicalutamide ) , estrogens ( e.g. , DES ) , surgical castration ( orchiectomy ) Use finasteride within 30 day prior registration . PSA obtain prior 30 day stop finasteride . Use dutasteride within 90 day prior registration . PSA obtain prior 90 day stop dutasteride . Previous concurrent cytotoxic chemotherapy prostate cancer Severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration Hepatic insufficiency result clinical jaundice and/or coagulation defect ; note , however , laboratory test liver function coagulation parameter require entry protocol . ( Patients Coumadin blood thin agent eligible study . ) Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition ; note , however , HIV test require entry protocol . The need exclude patient AIDS protocol necessary treatment involve protocol may significantly immunosuppressive . Protocolspecific requirement may also exclude immunocompromised patient .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>